Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2016—Horizon Discovery has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as immunohistochemistry reference standards in cancer tissue diagnostics to support the development and validation of IHC assays.
November 2016—MilliporeSigma introduced its Certified Spiking Solution of intact, heavy labeled thyroglobulin in SigMatrix, a synthetic surrogate serum.
November 2016—Siemens Healthineers released a software upgrade for its RapidComm Data Management System version 6.0, an informatics solution to centrally manage in vitro diagnostics analyzers and operators at the point of care. In addition to the system’s enhanced productivity and performance features, RapidComm V6.0 now connects with POC cardiac devices.
November 2016—Aalto Bio Reagents, a developer and provider of raw materials to the in vitro diagnostics industry and to research laboratories worldwide, announced the availability of its Tri-Plex suite of proteins and antibodies, which include its Zika Virus primary Envelope and NS1 proteins plus Chikungunya E2 wild type, E1 mutant, and E1 wild type proteins, and a complete set of Dengue virus proteins for serotypes 1–4.
November 2016—nzo Life Sciences introduced its new line of in situ hybridization and immunohistochemistry reagents for use with Enzo’s Highdef chromogens in ISH and IHC applications.
November 2016—Mindray has received 510(k) clearance from the Food and Drug Administration to market and sell the Mindray BC-5390 Auto Hematology Analyzer. The Mindray BC-5390 analyzer is designed to meet the testing needs of mid-volume hematology laboratories while offering features commonly found on large-volume analyzers.
November 2016—Sarstedt offers low protein binding micro tubes in 0.5 mL, 1.5 mL, and 2.0 mL volumes. These tubes are designed to meet the requirements of protein analytics while maximizing protein recovery rates. The micro tubes are manufactured from a proprietary polypropylene with low protein binding properties and do not feature any potentially contaminating surface coating like silicone.
November 2016—Meridian Life Science released a new catalog that provides a detailed overview of the company’s cardiac and metabolic markers for assay development. Meridian’s top-performing cardiac and metabolic markers include Lp-PLA2, CRP, D-dimer, troponin, NT-proBNP, myoglobin, procalcitonin, FABP, PAPP-A, fibrinogen, sCD40L, MPO, NSE, and galectin-3.
November 2016—U.K.-based Arcis Biotechnology launched its Arcis DNA Blood Kit (IVD) for preparation of DNA from blood using a novel three-minute, two-step system.
October 2016—ET Healthcare presented two posters at the meeting. Data from the abstract “A whole blood high-sensitivity cardiac troponin assay for POCT” showed that the Pylon cTnl assay met the definition of a fourth-generation high-sensitivity cardiac troponin I assay, with less than 10 percent CV at the 99th percentile and detection in greater than 95 percent of the reference population.
